Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial
Sera VA, Stevens AE, Song HK, Rodriguez VM, Tibayan FA, Treggiari MM. Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial. Pilot And Feasibility Studies 2021, 7: 137. PMID: 34215339, PMCID: PMC8252226, DOI: 10.1186/s40814-021-00873-5.Peer-Reviewed Original ResearchFactor Eight Inhibitor Bypassing ActivityCardiac surgeryPilot trialTransfusion requirementsRescue therapyLarge trialsProtocol adherenceBlood productsHigh-risk cardiac surgeryProthrombin complex concentrate administrationPlacebo-controlled pilot trialFactor VIII inhibitor bypass activityLarge pivotal trialsReduction of transfusionBlood product transfusionEnd of CPBTertiary referral hospitalHypothermic circulatory arrestTermination of CPBPost-cardiopulmonary bypassProthrombin complex concentrateBlinded administrationProduct transfusionResultsTwenty patientsStudy drug